BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lecouvet FE, Boyadzhiev D, Collette L, Berckmans M, Michoux N, Triqueneaux P, Pasoglou V, Jamar F, Vekemans MC. MRI versus 18F-FDG-PET/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance. Eur Radiol 2020;30:1927-37. [PMID: 31844960 DOI: 10.1007/s00330-019-06469-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Mulligan ME. Myeloma Response Assessment and Diagnosis System (MY-RADS): strategies for practice implementation. Skeletal Radiol 2021. [PMID: 33674886 DOI: 10.1007/s00256-021-03755-2] [Reference Citation Analysis]
2 Liu J, Li C, Yang X, Lu X, Zhang M, Qian L, Wang W, Kan Y, Yang J, Vali R. The Diagnostic Value of 18F-FDG PET/CT Bone Marrow Uptake Pattern in Detecting Bone Marrow Involvement in Pediatric Neuroblastoma Patients. Contrast Media & Molecular Imaging 2022;2022:1-9. [DOI: 10.1155/2022/7556315] [Reference Citation Analysis]
3 Sun M, Cheng J, Ren C, Zhang Y, Li Y, Wang L, Liu Y. Differentiation of Diffuse Infiltration Pattern in Multiple Myeloma From Hyperplastic Hematopoietic Bone Marrow: Qualitative and Quantitative Analysis Using Whole-Body MRI. J Magn Reson Imaging 2021. [PMID: 34558141 DOI: 10.1002/jmri.27934] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Burns R, Mulé S, Blanc-Durand P, Tofighi M, Belhadj K, Zerbib P, Le Bras F, Baranes L, Haioun C, Itti E, Luciani A. Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma. Eur Radiol 2021. [PMID: 34842956 DOI: 10.1007/s00330-021-08388-6] [Reference Citation Analysis]
5 Reinert CP, Krieg EM, Bösmüller H, Horger M. Mid-term response assessment in multiple myeloma using a texture analysis approach on dual energy-CT-derived bone marrow images - A proof of principle study. Eur J Radiol 2020;131:109214. [PMID: 32835853 DOI: 10.1016/j.ejrad.2020.109214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and Targeted Approaches in Multiple Myeloma. Immunotargets Ther 2020;9:201-15. [PMID: 33117743 DOI: 10.2147/ITT.S240886] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
7 Messiou C, Porta N, Sharma B, Levine D, Koh DM, Boyd K, Pawlyn C, Riddell A, Downey K, Croft J, Morgan V, Stern S, Cheung B, Kyriakou C, Kaczmarek P, Winfield J, Blackledge M, Oyen WJG, Kaiser MF. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiol Imaging Cancer 2021;3:e210048. [PMID: 34559006 DOI: 10.1148/rycan.2021210048] [Reference Citation Analysis]
8 Kharuzhyk S, Zhavrid E, Dziuban A, Sukolinskaja E, Kalenik O. Comparison of whole-body MRI with diffusion-weighted imaging and PET/CT in lymphoma staging. Eur Radiol 2020;30:3915-23. [PMID: 32103366 DOI: 10.1007/s00330-020-06732-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Moradi F, Iagaru A, McConathy J. Clinical Applications of PET/MR Imaging. Radiol Clin North Am 2021;59:853-74. [PMID: 34392923 DOI: 10.1016/j.rcl.2021.05.013] [Reference Citation Analysis]
10 Westerland O, Amlani A, Kelly-Morland C, Fraczek M, Bailey K, Gleeson M, El-Najjar I, Streetly M, Bassett P, Cook GJR, Goh V; Myeloma Imaging Research Group at Guy’s & St Thomas’ Hospital, London and King’s College London. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging 2021;48:2558-65. [PMID: 33469686 DOI: 10.1007/s00259-020-05182-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gallicchio R, Nardelli A, Calice G, Guarini A, Guglielmi G, Storto G. F-18 FDG PET/CT and F-18 FLT PET/CT as predictors of outcome in patients with multiple myeloma. A pilot study. Eur J Radiol 2021;136:109564. [PMID: 33517249 DOI: 10.1016/j.ejrad.2021.109564] [Reference Citation Analysis]
12 Paternain A, García-Velloso MJ, Rosales JJ, Ezponda A, Soriano I, Elorz M, Rodríguez-Otero P, Aquerreta JD. The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with 18F-FDG PET-CT. Eur J Radiol 2020;133:109403. [PMID: 33202373 DOI: 10.1016/j.ejrad.2020.109403] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Han S, Woo S, Kim YI, Yoon DH, Ryu JS. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis. Eur Radiol 2021;31:152-62. [PMID: 32809165 DOI: 10.1007/s00330-020-07177-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]